Список литературы

1. Бржезовский В.Ж. Опухоли щитовидной железы. В кн.: А.И. Пачес и др. Опухоли головы и шеи. 5-е изд., доп. и перераб. М.: Практическая медицина, 2013. С. 339 - 359.

2. Диагностика и лечение медуллярного рака щитовидной железы. национальные клинические рекомендации. Опухоли головы и шеи. 2013; (4): 36 - 45.

3. Газизова Д.О., Бельцевич Д.Г. Современный взгляд на проблему диагностики и лечения медуллярного рака щитовидной железы. Эндокринная хирургия 2013; (3): 4 - 21.

4. Wells S.A. Jr., Asa S.L., Dralle H., et al. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun; 25(6): 567 - 610. doi: 10.1089/thy.2014.0335.

5. Howlader N., Noone A.M., Krapcho M. et al. (eds). SEER Cancer Statistics Review, 1975 - 2014, National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2014

6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)). Thyroid Carcinoma. Version 4.2024 https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

7. Allelein S., Ehlers M., Morneau C., et al. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Horm Metab Res. 2018 Jan; 50(1): 23 - 28. doi: 10.1055/s-0043-122237.

8. Costante G., Meringolo D., Durante C., et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007 Feb; 92(2): 450-5. doi: 10.1210/jc.2006-1590.

9. Giannetta E., Guarnotta V., Altieri B., et al. ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. Eur J Endocrinol. 2020 Dec; 183(6): R197 - R215. doi: 10.1530/EJE-20-0506.

10. Северская Н.В., Ильин А.А., Чеботарева И.В. и др. Исследование кальцитонина у пациентов с узловыми образованиями щитовидной железы для скрининга медуллярного рака: "серая зона". Опухоли головы и шеи 2022; 12(2): 79 - 88. DOI: 10.17650/2222-1468-2022-12-2-79-88.

11. Trimboli P., Giannelli J., Marques B., et al. Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis. Endocrine. 2022 Jan; 75(1): 33 - 39. doi: 10.1007/s12020-021-02892-x.

12. Ильин А.А., Севрюков Ф.Е., Исаев П.А. и др. Дооперационная диагностика медуллярного рака щитовидной железы, сонографические находки//Злокачественные опухоли. - 2020. - Т. 10. - N 3S1. - С. 104 - 105. - EDN RYHGYA.

13. Alexander E.K., Cooper D. The importance, and important limitations, of ultrasound imaging for evaluating thyroid nodules. JAMA Intern Med. 2013 Oct 28; 173(19): 1796-7. doi: 10.1001/jamainternmed.2013.8278.

14. Friedrich-Rust M., Meyer G., Dauth N., et al. Interobserver agreement of Thyroid Imaging Reporting and Data System (TIRADS) and strain elastography for the assessment of thyroid nodules. PLoS One. 2013 Oct 24; 8(10): e77927. doi: 10.1371/journal.pone.0077927.

15. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan; 45(2): 228-47. doi: 10.1016/j.ejca.2008.10.026.

16. Trimboli P., Castellana M., Virili C., et al. Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2018 May 3; 9: 224. doi: 10.3389/fendo.2018.00224.

17. Ramos H.E., Hecht F., Berdelou A., et al. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer. Endocrine. 2021 Feb; 71(2): 434 - 442. doi: 10.1007/s12020-020-02426-x.

18. Elisei R., Schlumberger M.J., Muller S.P., et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29): 3639-46. doi: 10.1200/JCO.2012.48.4659.

19. Spitzweg C., Morris J.C., Bible K.C. New drugs for medullary thyroid cancer: new promises? Endocr Relat Cancer. 2016 Jun; 23(6): R287-97. doi: 10.1530/ERC-16-0104.

20. Capdevila J., Klochikhin A., Leboulleux S., et al. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid. 2022 May; 32(5): 515 - 524. doi: 10.1089/thy.2022.0027

21. Wirth L.J., Sherman E., Robinson B., et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27; 383(9): 825 - 835. doi: 10.1056/NEJMoa2005651.

22. Hadoux J., Elisei R., Brose M.S., et al. LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2309719.

23. Ravaud A., de la Fouchardiere C, Caron P, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer. 2017 May; 76: 110 - 117. doi: 10.1016/j.ejca.2017.01.029.

24. Bible K.C., Suman V.J., Molina J.R., et al. Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014 May; 99(5): 1687-93. doi: 10.1210/jc.2013-3713.

25. Schlumberger M., Jarzab B., Cabanillas M.E., et al. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 1; 22(1): 44 - 53. doi: 10.1158/1078-0432.CCR-15-1127.

26. Lam E.T., Ringel M.D., Kloos R.T., Prior T.W., Knopp M.V., Liang J., Sammet S., Hall N.C., Wakely P.E Jr., Vasko V.V., Saji M., Snyder P.J., Wei L., Arbogast D., Collamore M., Wright J.J., Moley J.F., Villalona-Calero M.A., Shah M.H. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10; 28(14): 2323-30. doi: 10.1200/JCO.2009.25.0068.

27. Marabelle A., Fakih M., Lopez J., et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct; 21(10): 1353 - 1365. doi: 10.1016/S1470-2045(20) 30445-9.

28. Terezakis S.A., Lee N.Y. The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Canc Netw. 2010 May; 8(5): 532-40; quiz 541. doi: 10.6004/jnccn.2010.0041.

29. Fromigue J., De Baere T., Baudin E., et al. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jul; 91(7): 2496-9. doi: 10.1210/jc.2005-2401.

30. Исаев П.А., Полькин В.В., Петров Л.О. и др. Хирургическое лечение метастазов медуллярного рака щитовидной железы в печень. Вопросы онкологии 2022; 68(4): https://doi.org/10.37469/0507-3758-2022-68-4-450-456

31. Kim I.Y., Kondziolka D., Niranjan A., et al. Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol. 2009 Jul; 93(3): 355-9. doi: 10.1007/s11060-008-9783-2.

32. Borcek P., Asa S.L., Gentili F., et al. Brain metastasis from medullary thyroid carcinoma. BMJ Case Rep. 2010 Dec 29; 2010. doi: 10.1136/bcr.09.2010.3301.

33. Breelyn A. Wilky, David M. Loeb. Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP. Clin Exp Pharmacol. 2013 Jun; 3(3): 1000131. doi: 10.4172/2161-1459.1000131

34. Reyhaneh Manafi-Farid, Fardad Masoumi, Ghasemali Divband, Bahare Saidi, Bahar Ataeinia, Fabian Hertel, Gregor Schweighofer-Zwink, Agnieszka Morgenroth, Mohsen Beheshti. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. J Clin Med. 2020 Aug 12; 9(8): 2622. doi: 10.3390/jcm9082622

35. Nicole M. Iniguez-Ariza,a,b Keith C. Bible,c,* and Bart L. Clarkea. Bone metastases in thyroid cancer. J Bone Oncol. 2020 Apr; 21: 100282.Published online 2020 Feb 19. doi: 10.1016/j.jbo.2020.100282

36. Giannetta E., Guarnotta V., Altieri B., et al. ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. Eur J Endocrinol. 2020 Dec; 183(6): R197 - R215. doi: 10.1530/EJE-20-0506. PMID: 33112280.

37. Niederle M.B., Scheuba C., Gessl A., et al. Calcium-stimulated calcitonin - the 'new standard' in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an 'old test'. Biochemia Medica 2018 28 030710. (doi: 10.11613/BM.2018.030710] 030710.

38. Поляков В.Г., Шишков Р.В., Ильин А.А. и др. Результаты профилактической тиреоидэктомии у носителей герминальной мутации в гене RET в семьях с наследственными формами медуллярного рака щитовидной железы. Клиническая и экспериментальная тиреоидология 2016; 12(1): 22 - 33. doi: 10.14341/ket2016122-33/

39. Hughes P., Healy N.A., Grant C., Ryan J.M. Treatment of hepatic metastases from medullary thyroid cancer with transarterial embolisation. Eur Radiol Exp. 2017; 1(1): 9. doi: 10.1186/s41747-017-0013-6

40. Kraft I.L., Akshintala S., Zhu Y., Lei H., et al. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clin Cancer Res. 2018 Feb 15; 24(4): 753 - 765. doi: 10.1158/1078-0432.CCR-17-2101.

41. Srivandana Akshintala et al. Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children"s Oncology Group Study (ADVL1622). JCO 39, 10010 - 10010(2021). DOI: 10.1200/JCO.2021.39.15_suppl.10010

42. Morgenstern D.A., et al. Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.. JCO 42, 10022 - 10022(2024). DOI: 10.1200/JCO.2024.42.16_suppl.10022

43. Asa S., Sonmezoglu K., Uslu-Besli L., et al. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Ann Nucl Med. 2021 Aug; 35(8): 900 - 915. doi: 10.1007/s12149-021-01627-2.